X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (14359) 14359
Newsletter (42) 42
Book Chapter (13) 13
Newspaper Article (12) 12
Magazine Article (7) 7
Transcript (4) 4
Dissertation (2) 2
Conference Proceeding (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11972) 11972
female (9126) 9126
paclitaxel (8221) 8221
oncology (7380) 7380
middle aged (7287) 7287
aged (6587) 6587
paclitaxel - administration & dosage (5655) 5655
chemotherapy (5638) 5638
male (5264) 5264
adult (5052) 5052
antineoplastic combined chemotherapy protocols - therapeutic use (4395) 4395
treatment outcome (4056) 4056
cancer (4028) 4028
paclitaxel - adverse effects (3851) 3851
antineoplastic combined chemotherapy protocols - adverse effects (3585) 3585
breast neoplasms - drug therapy (2365) 2365
cisplatin (2277) 2277
carboplatin (1965) 1965
trial (1933) 1933
drug administration schedule (1892) 1892
paclitaxel - therapeutic use (1892) 1892
docetaxel (1884) 1884
care and treatment (1861) 1861
pharmacology & pharmacy (1810) 1810
aged, 80 and over (1775) 1775
breast cancer (1760) 1760
lung neoplasms - drug therapy (1735) 1735
disease-free survival (1692) 1692
therapy (1665) 1665
carboplatin - administration & dosage (1610) 1610
animals (1607) 1607
neoplasm staging (1578) 1578
ovarian neoplasms - drug therapy (1478) 1478
antineoplastic agents, phytogenic - adverse effects (1455) 1455
carcinoma, non-small-cell lung - drug therapy (1440) 1440
medicine & public health (1431) 1431
research (1397) 1397
carcinoma (1328) 1328
cisplatin - administration & dosage (1325) 1325
antineoplastic combined chemotherapy protocols - administration & dosage (1263) 1263
survival (1251) 1251
time factors (1247) 1247
cardiac & cardiovascular systems (1235) 1235
breast neoplasms - pathology (1222) 1222
clinical trials (1208) 1208
antineoplastic agents - adverse effects (1193) 1193
antineoplastic agents, phytogenic - administration & dosage (1182) 1182
antineoplastic agents - therapeutic use (1178) 1178
combination (1162) 1162
ovarian cancer (1155) 1155
analysis (1137) 1137
antineoplastic agents (1132) 1132
metastasis (1118) 1118
drug therapy (1114) 1114
gemcitabine (1112) 1112
retrospective studies (1108) 1108
survival analysis (1098) 1098
dose-response relationship, drug (1087) 1087
deoxycytidine - analogs & derivatives (1076) 1076
survival rate (1068) 1068
antimitotic agents (1039) 1039
taxol (1039) 1039
doxorubicin (1017) 1017
risk factors (1014) 1014
cancer therapies (1001) 1001
follow-up studies (990) 990
bevacizumab (984) 984
hematology, oncology and palliative medicine (974) 974
prospective studies (973) 973
antineoplastic agents, phytogenic - therapeutic use (971) 971
tumors (959) 959
toxicity (955) 955
drug-eluting stents (930) 930
carboplatin - adverse effects (927) 927
patients (907) 907
deoxycytidine - administration & dosage (906) 906
stents (892) 892
surgery (890) 890
obstetrics & gynecology (887) 887
lung neoplasms - pathology (858) 858
antineoplastic agents - administration & dosage (848) 848
health aspects (848) 848
infusions, intravenous (822) 822
neoplasms - drug therapy (811) 811
phase-ii trial (807) 807
neoplasm metastasis (799) 799
cyclophosphamide (796) 796
prognosis (792) 792
taxoids (780) 780
kaplan-meier estimate (775) 775
paclitaxel - analogs & derivatives (773) 773
taxoids - administration & dosage (768) 768
combined modality therapy (757) 757
phase-ii (746) 746
carcinoma, non-small-cell lung - pathology (728) 728
restenosis (725) 725
neutropenia - chemically induced (722) 722
paclitaxel - pharmacology (696) 696
phase-iii trial (691) 691
mice (689) 689
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13986) 13986
Japanese (294) 294
Chinese (101) 101
German (71) 71
French (67) 67
Spanish (23) 23
Italian (19) 19
Russian (19) 19
Polish (11) 11
Korean (9) 9
Portuguese (6) 6
Hungarian (5) 5
Czech (4) 4
Danish (4) 4
Dutch (4) 4
Bulgarian (1) 1
Hebrew (1) 1
Lithuanian (1) 1
Romanian (1) 1
Slovenian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


04/2000, Volume 22, Issue 4, 40
Cytostatic antibiotics of the anthracycline class are the best known of the chemotherapeutic agents that cause cardiotoxicity. Alkylating agents such as... 
Mitomycin, adverse reactions | Tretinoin, adverse reactions | Etoposide, adverse reactions | Cladribine, adverse reactions | Heart disorders, drug-induced | Pentostatin, adverse reactions | Vinca alkaloids, adverse reactions | Cytostatic antibiotics, adverse reactions | Fluorouracil, adverse reactions | Asparaginase, adverse reactions | Cisplatin, adverse reactions | Carmustine, adverse reactions | Amsacrine, adverse reactions | Ifosfamide, adverse reactions | Mitoxantrone, adverse reactions | Cyclophosphamide, adverse reactions | Cytarabine, adverse reactions | Paclitaxel, adverse reactions | Teniposide, adverse reactions | Antineoplastics, adverse reactions | Busulfan, adverse reactions | Chlormethine, adverse reactions | HEMOLYTIC-UREMIC SYNDROME | SOFT-TISSUE SARCOMAS | HAIRY-CELL LEUKEMIA | PHASE-II TRIAL | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | BONE-MARROW TRANSPLANTATION | HIGH-DOSE CYCLOPHOSPHAMIDE | SOUTHWEST-ONCOLOGY-GROUP | ACUTE LYMPHOBLASTIC-LEUKEMIA | METASTATIC BREAST-CANCER | PHARMACOLOGY & PHARMACY | TOXICOLOGY | CONGESTIVE-HEART-FAILURE | Antineoplastic Agents - adverse effects | Humans | Risk Factors | Antimetabolites, Antineoplastic - adverse effects | Antibiotics, Antineoplastic - adverse effects | Heart Diseases - prevention & control | Antineoplastic Agents, Alkylating - adverse effects | Heart Diseases - chemically induced | Angiogenesis Inhibitors - adverse effects
Book Review
Nature Reviews Clinical Oncology, ISSN 1759-4774, 10/2009, Volume 6, Issue 10, pp. 596 - 603
...  REVIEWS Neurological adverse effects caused by cytotoxic and targeted therapies David Schiff, Patrick Y. Wen and Martin J. van den Bent Abstract... 
PHASE-II TRIAL | ONCOLOGY | POSTERIOR LEUKOENCEPHALOPATHY SYNDROME | ALBUMIN-BOUND PACLITAXEL | BRAIN-TUMOR CONSORTIUM | ACUTE TRANSIENT ENCEPHALOPATHY | CEREBROSPINAL-FLUID PHARMACOKINETICS | OXALIPLATIN-RELATED NEUROTOXICITY | RECURRENT MALIGNANT GLIOMAS | ANALOG IXABEPILONE BMS-247550 | ADVANCED COLORECTAL-CANCER | Dacarbazine - adverse effects | United States | Humans | Antibodies, Monoclonal - adverse effects | Boronic Acids - adverse effects | Drug Approval | Epothilones - adverse effects | Bevacizumab | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Dacarbazine - analogs & derivatives | Pyrroles - adverse effects | Angiogenesis Inhibitors - adverse effects | United States Food and Drug Administration | Tubulin Modulators - adverse effects | Bortezomib | Clinical Trials as Topic | Imatinib Mesylate | Piperazines - adverse effects | Neoplasms - drug therapy | Neurotoxicity Syndromes - etiology | Indoles - adverse effects | Pyrazines - adverse effects | Pyrimidines - adverse effects | Benzamides | Antineoplastic Agents, Alkylating - adverse effects | Organoplatinum Compounds - adverse effects | Antimitotic agents | Complications and side effects | Nervous system diseases | Patient outcomes | Dosage and administration | Genetic aspects | Research | Antineoplastic agents | Drug therapy | Risk factors | Cancer | Index Medicus
Journal Article
Chest, ISSN 0012-3692, 02/2008, Volume 133, Issue 2, pp. 528 - 538
Journal Article
Seminars in Diagnostic Pathology, ISSN 0740-2570, 2014, Volume 31, Issue 2, pp. 165 - 175
Journal Article
Annals of oncology, ISSN 0923-7534, 2018, Volume 29, Issue 3, pp. 646 - 653
Journal Article
Nature reviews. Clinical oncology, ISSN 1759-4782, 2009, Volume 6, Issue 8, pp. 465 - 477
.... with expanded clinical experience with this class of agents has come the increasing recognition of the diverse adverse effects related to disturbance of VEGF-dependent physiological functions... 
ONCOLOGY | POSTERIOR LEUKOENCEPHALOPATHY SYNDROME | TYROSINE KINASE INHIBITOR | PHASE-II | OVARIAN-CANCER | PACLITAXEL PLUS BEVACIZUMAB | THROMBOTIC MICROANGIOPATHY | METASTATIC COLORECTAL-CANCER | RENAL-CELL CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | COOPERATIVE-ONCOLOGY-GROUP | Humans | Antibodies, Monoclonal - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Benzenesulfonates - adverse effects | Bevacizumab | Brain Diseases - chemically induced | Benzenesulfonates - pharmacology | Pyridines - adverse effects | Drug Interactions | Kidney Diseases - chemically induced | Pyrroles - adverse effects | Angiogenesis Inhibitors - adverse effects | Antibodies, Monoclonal - pharmacology | Risk Factors | Angiogenesis Inhibitors - pharmacology | Forecasting | Indoles - adverse effects | Indoles - therapeutic use | Cardiovascular Diseases - chemically induced | Hemorrhage - chemically induced | Vascular Endothelial Growth Factor A - physiology | Niacinamide - analogs & derivatives | Receptors, Vascular Endothelial Growth Factor - physiology | Clinical Trials as Topic - statistics & numerical data | Neoplasm Proteins - physiology | Antibodies, Monoclonal - adverse effects | Cardiovascular Diseases - therapy | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Drug Delivery Systems | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Pyrroles - therapeutic use | Wound Healing - drug effects | Pyridines - therapeutic use | Hemorrhage - therapy | Pyrroles - pharmacology | Protein Kinase Inhibitors - therapeutic use | Capillary Leak Syndrome - chemically induced | Kidney Diseases - therapy | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Gastrointestinal Diseases - chemically induced | Antimitotic agents | Complications and side effects | Care and treatment | Colorectal cancer | Physiological aspects | Development and progression | Poisoning | Antineoplastic agents | Vascular endothelial growth factor | Risk factors | Tumors | Cancer | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2014, Volume 32, Issue 13, pp. 1302 - 1308
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 390, Issue 10103, pp. 1654 - 1663
Journal Article